Hims & Hers Health Inc has reiterated its 2025 revenue forecast after posting better-than-expected sales for the first ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell ...

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

The U.S. FDA has accepted the NDA for an oral formulation of Novo Nordisk A/S’s Wegovy (semaglutide) in treating obesity. If ...